- Home
- NPCE
NPCE
Neuropace Inc.
as 11-15-2024 4:00pm EST
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all its revenue from the sales of RNS System to hospitals facilities (typically Level 4 CECs) that implant RNS System.
| Founded: | 1997 | Country: | United States |
| Employees: | N/A | City: | MOUNTAIN VIEW |
| Market Cap: | 217.5M | IPO Year: | 2021 |
| Target Price: | $15.71 | AVG Volume (30 days): | 120.5K |
| Analyst Decision: | Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.99 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.45 - $18.15 | Next Earning Date: | 11-12-2024 |
| Revenue: | $76,452,000 | Revenue Growth: | 27.00% |
| Revenue Growth (this year): | 20.21% | Revenue Growth (next year): | 15.04% |
Stock Insider Trading Activity of Neuropace Inc. (NPCE)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| KCK LTD. | NPCE | 10% Owner | Oct 22 '24 | Sell | $6.09 | 4,082 | $24,853.26 | 5,494,983 | |
| KCK LTD. | NPCE | 10% Owner | Oct 18 '24 | Sell | $6.19 | 8,598 | $53,370.50 | 5,494,983 | |
| KCK LTD. | NPCE | 10% Owner | Oct 3 '24 | Sell | $6.49 | 46,426 | $303,366.79 | 5,494,983 | |
| KCK LTD. | NPCE | 10% Owner | Aug 30 '24 | Sell | $7.17 | 39,684 | $274,713.90 | 5,494,983 |
Latest Neuropace Inc. News
NPCE Breaking Stock News: Dive into NPCE Ticker-Specific Updates for Smart Investing
Simply Wall St.
4 days ago
NeuroPace Third Quarter 2024 Earnings: Beats Expectations
GuruFocus.com
5 days ago
NeuroPace Inc (NPCE) Q3 2024 Earnings Call Highlights: Record Revenue and Strategic Growth ...
Zacks
5 days ago
NeuroPace, Inc. (NPCE) Reports Q3 Loss, Tops Revenue Estimates
Associated Press Finance
5 days ago
NeuroPace Inc.: Q3 Earnings Snapshot
GlobeNewswire
5 days ago
NeuroPace Reports Third Quarter 2024 Financial Results and Increases 2024 Revenue Guidance
GuruFocus.com
6 days ago
Earnings To Watch: NeuroPace Inc (NPCE) Reports Q3 2024 Result
Simply Wall St.
8 days ago
private equity firms who own 45% along with institutions invested in NeuroPace, Inc. (NASDAQ:NPCE) saw increase in their holdings value last week
GlobeNewswire
13 days ago
NeuroPace Announces FDA Submission of Three-Year Data from Post-Approval Study of the RNS System in Focal Epilepsy
Compare NPCE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NPCE Neuropace Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.